Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Crucell
|
| gptkbp:age |
4 to 6 years
12 to 15 months |
| gptkbp:associated_with |
herd immunity
|
| gptkbp:availability |
widely available
|
| gptkbp:average_temperature |
-15° C or lower
|
| gptkbp:brand |
gptkb:Varivax
|
| gptkbp:clinical_trial |
conducted for safety and efficacy
|
| gptkbp:complement |
MMRV (measles, mumps, rubella, varicella)
|
| gptkbp:contraindication |
pregnant women
immunocompromised individuals |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
not routinely recommended
|
| gptkbp:healthcare |
routine childhood vaccination
reduced incidence of chickenpox |
| https://www.w3.org/2000/01/rdf-schema#label |
Varicella vaccine
|
| gptkbp:introduced |
gptkb:1995
|
| gptkbp:is_effective_against |
about 90% effective
|
| gptkbp:is_vulnerable_to |
varies by region
updated periodically ongoing improvements post-marketing surveillance exists in some populations important for parents through healthcare providers monovalent vaccine significantly reduced hospitalizations continues for new formulations decreased mortality rates from chickenpox lowered healthcare costs associated with chickenpox |
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:price |
varies by country
|
| gptkbp:public_awareness |
increased through campaigns
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:research_focus |
long-term immunity
|
| gptkbp:side_effect |
fever
tiredness mild rash anaphylaxis (rare) |
| gptkbp:suitable_for |
gptkb:Person
gptkb:CDC gptkb:WHO |
| gptkbp:supply_chain |
managed by manufacturers
|
| gptkbp:targets |
chickenpox
|
| gptkbp:type |
live attenuated vaccine
|